

## Intra-Cellular Therapies to Present at the 21st Annual Needham Virtual Healthcare Conference

April 5, 2022

NEW YORK, April 05, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022 at 11:00 am ET.

The live and archived webcast can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at <a href="https://www.intracellulartherapies.com">www.intracellulartherapies.com</a>. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.

## **About Intra-Cellular Therapies**

Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases. For more information, please visit <a href="https://www.intracellulartherapies.com">www.intracellulartherapies.com</a>.

## Contact:

Intra-Cellular Therapies, Inc. Juan Sanchez, M.D. Vice President, Corporate Communications and Investor Relations 646-440-9333

Burns McClellan, Inc. Lisa Burns <u>cradinovic@burnsmc.com</u> 212-213-0006



Source: Intra-Cellular Therapies Inc.